Krayacich appointed to head Marinus Pharma

By Mass High Tech Staff

GI Dynamics secures $15M investment [February 9, 2009]

Canaan Partners invests in N.Y. online video firm [January 15, 2009]

Inside New York/New England connections: N.Y. new media pull from Boston VCs, technology [January 9, 2009]

Healthcare Ventures, Novartis BioVentures help raise $40M for Catalyst Biosciences [December 4, 2008]

Marinus Pharmaceuticals Inc. has named John Krayacich as president and CEO of the Branford, Conn.-based developer of neurological, psychiatric and pain disorder treatments.

Krayacich will head development of chelerythrine, a pre-clinical schizophrenia drug candidate, and ganaxolone, a Phase 2 drug candidate for adult and pediatric epilepsy.

Prior to joining Marinus, Krayacich worked for Novartis Pharmaceuticals Corp. as global program head for the antidepressant agomelatine, and vice president and global head of neuroscience project management.

He has also served as vice president of worldwide neurology marketing at Pfizer Pharmaceuticals Group and Parke-Davis Global Marketing Planning. Krayacich also has helped develop and market treatments for epilepsy, Parkinson’s disease, Alzheimer’s disease, neuropathic pain, depression, anxiety, Multiple Sclerosis and bipolar disorder.

Marinus Pharmaceuticals is a privately-held company with investment backing from Domain Associates, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.